Phase I Dose-Escalation Study to Determine the Safety and Tolerability of an Intratumoural Injection of EBC-46
Phase of Trial: Phase I
Latest Information Update: 16 Jul 2019
Price : $35 *
At a glance
- Drugs Tigilanol tiglate (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors QBiotics
- 08 Jul 2017 Status changed from recruiting to completed.
- 06 Sep 2016 Planned number of patients changed from 30 to 15.
- 26 Nov 2014 Status changed from not yet recruiting to recruiting, as reported by Australian New Zealand Clinical Trials Registry.